{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T22:29:56Z","timestamp":1777674596708,"version":"3.51.4"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:00:00Z","timestamp":1761609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:00:00Z","timestamp":1761609600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82371808"],"award-info":[{"award-number":["82371808"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s10067-025-07706-3","type":"journal-article","created":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T10:13:27Z","timestamp":1761646407000},"page":"257-269","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical practice guideline for the treatment of Sj\u00f6gren\u2019s disease through off-label drug use in China (English edition)"],"prefix":"10.1007","volume":"45","author":[{"given":"Yingqian","family":"Mo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingxin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6596-8889","authenticated-orcid":false,"given":"Lie","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Committee for Rheumatologists, Immunologists of the Chinese Primary Health Care Foundation","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,28]]},"reference":[{"issue":"4","key":"7706_CR1","doi-asserted-by":"publisher","first-page":"269","DOI":"10.3760\/cma.j.cn112138-20200113-00021","volume":"59","author":"W Zhang","year":"2020","unstructured":"Zhang W, Li XM, Xu D et al (2020) Diagnostic and Treatment Norms for Primary Sj\u00f6gren\u2019s Syndrome. Chinese J Internal Med 59(4):269\u2013276. https:\/\/doi.org\/10.3760\/cma.j.cn112138-20200113-00021","journal-title":"Chinese J Internal Med"},{"issue":"4","key":"7706_CR2","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","volume":"64","author":"G Guyatt","year":"2011","unstructured":"Guyatt G, Oxman AD, Akl EA et al (2011) GRADE guidelines: 1. Introduction-grade evidence profiles and summary of findings tables. J Clin Epidemiol 64(4):383\u2013394. https:\/\/doi.org\/10.1016\/j.jclinepi.2010.04.026","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"7706_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/annrheumdis-2019-216114","volume":"79","author":"M Ramos-Casals","year":"2020","unstructured":"Ramos-Casals M, Brito-Zer\u00f3n P, Bombardieri S et al (2020) EULAR recommendations for the management of Sj\u00f6gren\u2019s syndrome with topical and systemic therapies. Ann Rheum Dis 79(1):3\u201318. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216114","journal-title":"Ann Rheum Dis"},{"key":"7706_CR4","doi-asserted-by":"publisher","unstructured":"Se C, Fb V, AP, et al (2017) Treatment guidelines for rheumatologic manifestations of Sj\u00f6gren\u2019s syndrome: use of biologic agents, management of fatigue, and inflammatory musculoskeletal pain. Arthritis Care Res 69(4). https:\/\/doi.org\/10.1002\/acr.22968","DOI":"10.1002\/acr.22968"},{"issue":"2","key":"7706_CR5","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.chest.2020.10.011","volume":"159","author":"AS Lee","year":"2021","unstructured":"Lee AS, Scofield RH, Hammitt KM et al (2021) Consensus guidelines for evaluation and management of pulmonary disease in Sj\u00f6gren\u2019s. Chest 159(2):683\u2013698. https:\/\/doi.org\/10.1016\/j.chest.2020.10.011","journal-title":"Chest"},{"issue":"7","key":"7706_CR6","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1136\/annrheumdis-2021-222054","volume":"81","author":"R Seror","year":"2022","unstructured":"Seror R, Baron G, Camus M et al (2022) Development and preliminary validation of the Sj\u00f6gren\u2019s tool for assessing response (STAR): a consensual composite score for assessing treatment effect in primary Sj\u00f6gren\u2019s syndrome. Ann Rheum Dis 81(7):979\u2013989. https:\/\/doi.org\/10.1136\/annrheumdis-2021-222054","journal-title":"Ann Rheum Dis"},{"key":"7706_CR7","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1080\/15027732.1986.12461423","volume":"61","author":"MT Walters","year":"1986","unstructured":"Walters MT, Rubin CE, Keightley SJ, Ward CD, Cawley MI (1986) A double-blind, cross-over, study of oral N-acetylcysteine in Sj\u00f6gren\u2019s syndrome. Scand J Rheumatol Suppl 61:253\u2013258","journal-title":"Scand J Rheumatol Suppl"},{"issue":"4","key":"7706_CR8","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1055\/s-2008-1054619","volume":"185","author":"V Fossaluzza","year":"1984","unstructured":"Fossaluzza V (1984) Bromhexine in symptomatic treatment of Sj\u00f6gren syndrome. Klin Monbl Augenheilkd 185(4):292\u2013295. https:\/\/doi.org\/10.1055\/s-2008-1054619","journal-title":"Klin Monbl Augenheilkd"},{"issue":"5","key":"7706_CR9","doi-asserted-by":"publisher","first-page":"e260","DOI":"10.1016\/S2665-9913(20)30057-6","volume":"2","author":"EHM van der Heijden","year":"2020","unstructured":"van der Heijden EHM, Blokland SLM, Hillen MR et al (2020) Leflunomide-hydroxychloroquine combination therapy in patients with primary Sj\u00f6gren\u2019s syndrome (RepurpSS-I): a placebo-controlled, double-blinded, randomised clinical trial. Lancet Rheumatol 2(5):e260\u2013e269. https:\/\/doi.org\/10.1016\/S2665-9913(20)30057-6","journal-title":"Lancet Rheumatol"},{"issue":"13","key":"7706_CR10","doi-asserted-by":"publisher","first-page":"34","DOI":"10.16458\/j.cnki.1007-0893.2017.13.017","volume":"27","author":"W Xiaohan","year":"2017","unstructured":"Xiaohan W (2017) The effect of tripterygium glycosides combined with total glycosides of paeonia on salivary flow rate in patients with Sj\u00f6gren\u2019s syndrome. J Integrated Traditional Western Med Shenzhen 27(13):34\u201335. https:\/\/doi.org\/10.16458\/j.cnki.1007-0893.2017.13.017","journal-title":"J Integrated Traditional Western Med Shenzhen"},{"issue":"7","key":"7706_CR11","doi-asserted-by":"publisher","first-page":"114","DOI":"10.19347\/j.cnki.2096-1413.201807055","volume":"3","author":"Q Jianhong","year":"2018","unstructured":"Jianhong Q, Xingcun X (2018) Clinical effect of blood-activating and toxin-resolving formula in treating primary Sj\u00f6gren\u2019s syndrome. Clin Med Res Pract 3(7):114\u2013115. https:\/\/doi.org\/10.19347\/j.cnki.2096-1413.201807055","journal-title":"Clin Med Res Pract"},{"issue":"3","key":"7706_CR12","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1001\/jama.2014.7682","volume":"312","author":"JE Gottenberg","year":"2014","unstructured":"Gottenberg JE, Ravaud P, Pu\u00e9chal X et al (2014) Effects of hydroxychloroquine on symptomatic improvement in primary Sj\u00f6gren syndrome: the JOQUER randomized clinical trial. JAMA 312(3):249\u2013258. https:\/\/doi.org\/10.1001\/jama.2014.7682","journal-title":"JAMA"},{"issue":"2","key":"7706_CR13","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1080\/03009742.2020.1809701","volume":"50","author":"Q Shao","year":"2021","unstructured":"Shao Q, Wang S, Jiang H, Liu L (2021) Efficacy and safety of iguratimod on patients with primary Sj\u00f6gren\u2019s syndrome: a randomized, placebo-controlled clinical trial. Scand J Rheumatol 50(2):143\u2013152. https:\/\/doi.org\/10.1080\/03009742.2020.1809701","journal-title":"Scand J Rheumatol"},{"issue":"5","key":"7706_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/ar4359","volume":"15","author":"F Carubbi","year":"2013","unstructured":"Carubbi F, Cipriani P, Marrelli A et al (2013) Efficacy and safety of rituximab treatment in early primary Sj\u00f6gren\u2019s syndrome: a prospective, multi-center, follow-up study. Arthritis Res Ther 15(5):R172. https:\/\/doi.org\/10.1186\/ar4359","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"7706_CR15","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1002\/art.27314","volume":"62","author":"JM Meijer","year":"2010","unstructured":"Meijer JM, Meiners PM, Vissink A et al (2010) Effectiveness of rituximab treatment in primary Sj\u00f6gren\u2019s syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 62(4):960\u2013968. https:\/\/doi.org\/10.1002\/art.27314","journal-title":"Arthritis Rheum"},{"issue":"7","key":"7706_CR16","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1002\/art.40093","volume":"69","author":"SJ Bowman","year":"2017","unstructured":"Bowman SJ, Everett CC, O\u2019Dwyer JL et al (2017) Randomized controlled trial of Rituximab and cost-effectiveness analysis in treating fatigue and oral dryness in primary Sj\u00f6gren\u2019s syndrome. Arthritis Rheumatol 69(7):1440\u20131450. https:\/\/doi.org\/10.1002\/art.40093","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"7706_CR17","doi-asserted-by":"publisher","first-page":"179","DOI":"10.7661\/CJIM.2017.02.0179","volume":"37","author":"Xu Hu Wei","year":"2017","unstructured":"Hu Wei Xu, Changsong LX et al (2017) Efficacy and safety of Liu Jin Run Zao concentrated decoction in treating primary Sj\u00f6gren\u2019s syndrome. Chinese J Integrated Tradit Western Med 37(2):179\u2013183. https:\/\/doi.org\/10.7661\/CJIM.2017.02.0179","journal-title":"Chinese J Integrated Tradit Western Med"},{"issue":"3","key":"7706_CR18","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/s10067-018-4315-8","volume":"38","author":"X Liu","year":"2019","unstructured":"Liu X, Li X, Li X et al (2019) The efficacy and safety of total glucosides of peony in the treatment of primary Sj\u00f6gren\u2019s syndrome: a multi-center, randomized, double-blinded, placebo-controlled clinical trial. Clin Rheumatol 38(3):657\u2013664. https:\/\/doi.org\/10.1007\/s10067-018-4315-8","journal-title":"Clin Rheumatol"},{"issue":"11","key":"7706_CR19","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3969\/j.issn.1000-0704.2010.11.017","volume":"32","author":"He Hao","year":"2010","unstructured":"Hao He (2010) Clinical observation of paeoniflorin combined with hydroxychloroquine in treating Sj\u00f6gren\u2019s syndrome. Hubei J Tradit Chinese Med 32(11):30\u201331. https:\/\/doi.org\/10.3969\/j.issn.1000-0704.2010.11.017","journal-title":"Hubei J Tradit Chinese Med"},{"issue":"35","key":"7706_CR20","first-page":"20","volume":"8","author":"B Yin","year":"2011","unstructured":"Yin B (2011) Clinical observation of pafurin combined with hydroxychloroquine sulfate in treating Sj\u00f6gren\u2019s syndrome without systemic involvement. Chin Med Innov 8(35):20\u201321","journal-title":"Chin Med Innov"},{"issue":"4","key":"7706_CR21","doi-asserted-by":"publisher","first-page":"530","DOI":"10.16367\/j.issn.1003-5028.2013.04.083","volume":"33","author":"Z Hao","year":"2013","unstructured":"Hao Z, Futao Z (2013) Clinical study of paeoniflorin combined with hydroxychloroquine in treating primary Sj\u00f6gren\u2019s syndrome. Henan J Tradit Chinese Med 33(4):530\u2013531. https:\/\/doi.org\/10.16367\/j.issn.1003-5028.2013.04.083","journal-title":"Henan J Tradit Chinese Med"},{"key":"7706_CR22","unstructured":"You Yaqi (2015) Summary of professor Wang Weigang\u2019s clinical experience in treating Sj\u00f6gren\u2019s syndrome and preliminary clinical efficacy of paeoniflorin in treating Sj\u00f6gren\u2019s syndrome [D]. Beijing Univ Chinese Med, 2015."},{"issue":"9","key":"7706_CR23","doi-asserted-by":"publisher","first-page":"915","DOI":"10.3969\/j.issn.1671-6450.2017.09.013","volume":"16","author":"Xu Dong","year":"2017","unstructured":"Dong Xu, Xiaowei Lv, Peng C et al (2017) Comparison of the Efficacy and Safety of Ixazomib and Hydroxychloroquine in Treating Patients with Sj\u00f6gren\u2019s Syndrome. J Difficult Complicated Cases 16(9):915\u2013918. https:\/\/doi.org\/10.3969\/j.issn.1671-6450.2017.09.013","journal-title":"J Difficult Complicated Cases"},{"issue":"4","key":"7706_CR24","doi-asserted-by":"publisher","first-page":"452","DOI":"10.3969\/j.issn.1000-7377.2019.04.012","volume":"48","author":"Z Jing","year":"2019","unstructured":"Jing Z, Siyao S (2019) Efficacy and mechanism of Ixazomib in treating Sj\u00f6gren\u2019s syndrome. Shaanxi Med J 48(4):452\u2013455. https:\/\/doi.org\/10.3969\/j.issn.1000-7377.2019.04.012","journal-title":"Shaanxi Med J"},{"issue":"32","key":"7706_CR25","doi-asserted-by":"publisher","first-page":"103","DOI":"10.15912\/j.cnki.gocm.2019.32.081","volume":"17","author":"Z Xiaoyan","year":"2019","unstructured":"Xiaoyan Z (2019) Comparative observation of Ixazomib and hydroxychloroquine in treating patients with Sj\u00f6gren\u2019s syndrome. Guide China Med 17(32):103. https:\/\/doi.org\/10.15912\/j.cnki.gocm.2019.32.081","journal-title":"Guide China Med"},{"issue":"9","key":"7706_CR26","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1136\/ard.45.9.732","volume":"45","author":"AA Drosos","year":"1986","unstructured":"Drosos AA, Skopouli FN, Costopoulos JS, Papadimitriou CS, Moutsopoulos HM (1986) Cyclosporin A (CyA) in primary Sj\u00f6gren\u2019s syndrome: a double blind study. Ann Rheum Dis 45(9):732\u2013735. https:\/\/doi.org\/10.1136\/ard.45.9.732","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"7706_CR27","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.3346\/jkms.2016.31.7.1127","volume":"31","author":"CH Yoon","year":"2016","unstructured":"Yoon CH, Lee HJ, Lee EY et al (2016) Effect of hydroxychloroquine treatment on dry eyes in subjects with primary Sj\u00f6gren\u2019s syndrome: a double-blind randomized control study. J Korean Med Sci 31(7):1127\u20131135. https:\/\/doi.org\/10.3346\/jkms.2016.31.7.1127","journal-title":"J Korean Med Sci"},{"key":"7706_CR28","unstructured":"Song Z (2014) Clinical efficacy observation of Zao Bi Qing in treating primary Sj\u00f6gren\u2019s syndrome [D]. Shandong Univ Tradit Chinese Med, 2014"},{"issue":"4","key":"7706_CR29","doi-asserted-by":"publisher","first-page":"233","DOI":"10.7326\/M13-1085","volume":"160","author":"V Devauchelle-Pensec","year":"2014","unstructured":"Devauchelle-Pensec V, Mariette X, Jousse-Joulin S et al (2014) Treatment of primary Sj\u00f6gren syndrome with rituximab: a randomized trial. Ann Intern Med 160(4):233\u2013242. https:\/\/doi.org\/10.7326\/M13-1085","journal-title":"Ann Intern Med"},{"key":"7706_CR30","unstructured":"Cui M (2012) Clinical and experimental study on the intervention of blood-activating, toxin-resolving, yin-nourishing and fluid-generating formula in Sj\u00f6gren\u2019s syndrome [D]. Beijing Univ Chinese Med, 2012"},{"issue":"7","key":"7706_CR31","doi-asserted-by":"publisher","first-page":"770","DOI":"10.16466\/j.issn1005-5509.2012.07.037","volume":"36","author":"G Yuke","year":"2012","unstructured":"Yuke G, Chenggong M, Wei J (2012) Efficacy analysis of tripterygium glycosides tablets in treating hypergammaglobulinemia in primary Sj\u00f6gren\u2019s syndrome. J Zhejiang Chinese Med Univ 36(7):770\u2013772. https:\/\/doi.org\/10.16466\/j.issn1005-5509.2012.07.037","journal-title":"J Zhejiang Chinese Med Univ"},{"key":"7706_CR32","doi-asserted-by":"publisher","unstructured":"Ma C (2012) Study on the effect of tripterygium glycosides tablets on hypergammaglobulinemia in primary Sj\u00f6gren\u2019s Syndrome [D]. Nanjing Univ Chinese Med 2012. https:\/\/doi.org\/10.7666\/d.y2124539","DOI":"10.7666\/d.y2124539"},{"issue":"12","key":"7706_CR33","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.3969\/j.issn.1000-744X.2018.12.018","volume":"42","author":"J Yi","year":"2018","unstructured":"Yi J, Nian Z (2018) The effect of tripterygium glycosides combined with paeoniflorin on the serum Th17\/Treg balance and immune function in patients with Sj\u00f6gren\u2019s syndrome. Guizhou Med J 42(12):1446\u20131447. https:\/\/doi.org\/10.3969\/j.issn.1000-744X.2018.12.018","journal-title":"Guizhou Med J"},{"issue":"8","key":"7706_CR34","doi-asserted-by":"publisher","first-page":"90","DOI":"10.3969\/j.issn.1002-3429.2016.08.029","volume":"29","author":"J Dexun","year":"2016","unstructured":"Dexun J, Yunjing B, Liping Z et al (2016) Clinical observation of iguratimod combined therapy in treating primary Sj\u00f6gren\u2019s syndrome. Clin Misdiagnosis Mistreatment 29(8):90\u201393. https:\/\/doi.org\/10.3969\/j.issn.1002-3429.2016.08.029","journal-title":"Clin Misdiagnosis Mistreatment"},{"issue":"6","key":"7706_CR35","doi-asserted-by":"publisher","first-page":"150","DOI":"10.15912\/j.cnki.gocm.2020.06.122","volume":"18","author":"Y Weijing","year":"2020","unstructured":"Weijing Y (2020) Clinical analysis of iguratimod in treating primary Sj\u00f6gren\u2019s syndrome. Guide China Med 18(6):150. https:\/\/doi.org\/10.15912\/j.cnki.gocm.2020.06.122","journal-title":"Guide China Med"},{"issue":"18","key":"7706_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3969\/j.issn.1672-0369.2020.18.001","volume":"32","author":"Gu Jing","year":"2020","unstructured":"Jing Gu (2020) Clinical effect of methylprednisolone combined with iguratimod in treating elderly patients with primary Sj\u00f6gren\u2019s syndrome. Chinese J People\u2019s Health 32(18):1\u20132. https:\/\/doi.org\/10.3969\/j.issn.1672-0369.2020.18.001","journal-title":"Chinese J People\u2019s Health"},{"issue":"17","key":"7706_CR37","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3969\/j.issn.1672-0369.2019.17.015","volume":"31","author":"Z Ling","year":"2019","unstructured":"Ling Z (2019) Observation on the effect of methylprednisolone combined with iguratimod in treating primary Sj\u00f6gren\u2019s syndrome. Chin J Peoples Health 31(17):35\u201336. https:\/\/doi.org\/10.3969\/j.issn.1672-0369.2019.17.015","journal-title":"Chin J Peoples Health"},{"issue":"4","key":"7706_CR38","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1002\/art.39518","volume":"68","author":"G Nocturne","year":"2016","unstructured":"Nocturne G, Virone A, Ng WF et al (2016) Rheumatoid factor and disease activity are independent predictors of lymphoma in primary Sj\u00f6gren\u2019s syndrome. Arthritis Rheumatol 68(4):977\u2013985. https:\/\/doi.org\/10.1002\/art.39518","journal-title":"Arthritis Rheumatol"},{"key":"7706_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2022.151955","volume":"53","author":"L de Wolff","year":"2022","unstructured":"de Wolff L, van Nimwegen JF, Mossel E et al (2022) Long-term abatacept treatment for 48 weeks in patients with primary Sj\u00f6gren\u2019s syndrome: the open-label extension phase of the ASAP-III trial. Semin Arthritis Rheum 53:151955. https:\/\/doi.org\/10.1016\/j.semarthrit.2022.151955","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"7706_CR40","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.autrev.2018.06.015","volume":"18","author":"A Mirouse","year":"2018","unstructured":"Mirouse A, Seror R, Vicaut E et al (2018) Arthritis in primary Sj\u00f6gren\u2019s syndrome: Characteristics, outcome and treatment from French multicenter retrospective study. Autoimmun Rev 18(1):9\u201314. https:\/\/doi.org\/10.1016\/j.autrev.2018.06.015","journal-title":"Autoimmun Rev"},{"issue":"9","key":"7706_CR41","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1007\/s10067-016-3360-4","volume":"35","author":"C Kedor","year":"2016","unstructured":"Kedor C, Zernicke J, Hagemann A et al (2016) A phase II investigator-initiated pilot study with low-dose cyclosporine A for the treatment of articular involvement in primary Sj\u00f6gren\u2019s syndrome. Clin Rheumatol 35(9):2203\u20132210. https:\/\/doi.org\/10.1007\/s10067-016-3360-4","journal-title":"Clin Rheumatol"},{"issue":"12","key":"7706_CR42","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1111\/1756-185X.14023","volume":"23","author":"Y Xu","year":"2020","unstructured":"Xu Y, Zhou J, Dong X, Guo X, Lu Y, Zheng Y (2020) Risk factors for progression and prognosis of primary Sj\u00f6gren\u2019s syndrome-associated interstitial lung disease in a Chinese population. Int J Rheum Dis 23(12):1734\u20131740. https:\/\/doi.org\/10.1111\/1756-185X.14023","journal-title":"Int J Rheum Dis"},{"issue":"2","key":"7706_CR43","doi-asserted-by":"publisher","first-page":"136","DOI":"10.36141\/svdld.v37i2.8461","volume":"37","author":"B Amlani","year":"2020","unstructured":"Amlani B, Elsayed G, Barvalia U et al (2020) Treatment of primary Sj\u00f6gren\u2019s syndrome-related interstitial lung disease: a retrospective cohort study. Sarcoidosis Vasc Diffuse Lung Dis 37(2):136\u2013147. https:\/\/doi.org\/10.36141\/svdld.v37i2.8461","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"6","key":"7706_CR44","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.pulmoe.2021.06.004","volume":"27","author":"G Klinowski","year":"2021","unstructured":"Klinowski G, Gozzi F, Trentacosti F, Andrisani D, Sebastiani M, Clini EM (2021) Rituximab for the treatment of acute onset interstitial lung disease in primary Sjogren\u2019s syndrome. Pulmonology 27(6):575\u2013578. https:\/\/doi.org\/10.1016\/j.pulmoe.2021.06.004","journal-title":"Pulmonology"},{"issue":"8","key":"7706_CR45","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1097\/RHU.0b013e31823ac199","volume":"17","author":"MA Swartz","year":"2011","unstructured":"Swartz MA, Vivino FB (2011) Dramatic reversal of lymphocytic interstitial pneumonitis in Sj\u00f6gren\u2019s syndrome with rituximab. J Clin Rheumatol 17(8):454. https:\/\/doi.org\/10.1097\/RHU.0b013e31823ac199","journal-title":"J Clin Rheumatol"},{"issue":"6","key":"7706_CR46","first-page":"1077","volume":"34","author":"MH Chen","year":"2016","unstructured":"Chen MH, Chen CK, Chou HP, Chen MH, Tsai CY, Chang DM (2016) Rituximab therapy in primary Sj\u00f6gren\u2019s syndrome with interstitial lung disease: a retrospective cohort study. Clin Exp Rheumatol 34(6):1077\u20131084","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"7706_CR47","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1007\/BF01452266","volume":"17","author":"H Ogasawara","year":"1998","unstructured":"Ogasawara H, Sekiya M, Murashima A et al (1998) Very low-dose cyclosporin treatment of steroid-resistant interstitial pneumonitis associated with Sj\u00f6gren\u2019s syndrome. Clin Rheumatol 17(2):160\u2013162. https:\/\/doi.org\/10.1007\/BF01452266","journal-title":"Clin Rheumatol"},{"key":"7706_CR48","doi-asserted-by":"publisher","unstructured":"HO, AM, HK, et al (1998) Effect of low-dose cyclosporin treatment on interstitial pneumonitis associated with Sj\u00f6gren\u2019s syndrome. British journal of rheumatology. 37(3). https:\/\/doi.org\/10.1093\/rheumatology\/37.3.348","DOI":"10.1093\/rheumatology\/37.3.348"},{"issue":"12","key":"7706_CR49","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.55563\/clinexprheumatol\/5c7l01","volume":"40","author":"R Xu","year":"2022","unstructured":"Xu R, Yan Q, Gong Y et al (2022) Tacrolimus therapy in primary Sj\u00f6gren\u2019s syndrome with refractory immune thrombocytopenia: a retrospective study. Clin Exp Rheumatol 40(12):2268\u20132274. https:\/\/doi.org\/10.55563\/clinexprheumatol\/5c7l01","journal-title":"Clin Exp Rheumatol"},{"issue":"7","key":"7706_CR50","doi-asserted-by":"publisher","first-page":"486","DOI":"10.3760\/cma.j.issn.1671-7368.2009.07.022","volume":"8","author":"W Yan","year":"2009","unstructured":"Yan W, Baoliang Lv, Shaoting W et al (2009) Clinical observation of prednisone combined with cyclosporine a in treating Sj\u00f6gren\u2019s syndrome with thrombocytopenia. Chinese J Gen Pract 8(7):486\u2013488. https:\/\/doi.org\/10.3760\/cma.j.issn.1671-7368.2009.07.022","journal-title":"Chinese J Gen Pract"},{"issue":"5","key":"7706_CR51","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1097\/RHU.0000000000000273","volume":"21","author":"B Jiang","year":"2015","unstructured":"Jiang B, Li T, Guo L, Shen H, Ye S, Chen S (2015) Efficacy and safety of Rituximab in systemic lupus erythematosus and Sj\u00f6gren syndrome patients with refractory thrombocytopenia: a retrospective study of 21 cases. J Clin Rheumatol 21(5):244\u2013250. https:\/\/doi.org\/10.1097\/RHU.0000000000000273","journal-title":"J Clin Rheumatol"},{"issue":"10","key":"7706_CR52","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1007\/s10067-020-05152-x","volume":"39","author":"F Sun","year":"2020","unstructured":"Sun F, Chen J, Wu W et al (2020) Rituximab or cyclosporin in refractory immune thrombocytopenia secondary to connective tissue diseases: a real-world observational retrospective study. Clin Rheumatol 39(10):3099\u20133104. https:\/\/doi.org\/10.1007\/s10067-020-05152-x","journal-title":"Clin Rheumatol"},{"issue":"11","key":"7706_CR53","doi-asserted-by":"publisher","first-page":"e2241451","DOI":"10.1001\/jamanetworkopen.2022.41451","volume":"5","author":"J He","year":"2022","unstructured":"He J, Chen J, Miao M et al (2022) Efficacy and safety of low-dose interleukin 2 for primary Sj\u00f6gren syndrome: a randomized clinical trial. JAMA Netw Open 5(11):e2241451. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.41451","journal-title":"JAMA Netw Open"},{"key":"7706_CR54","doi-asserted-by":"publisher","unstructured":"JK, KM, Ht K, et al (2011) Interleukin-2 and regulatory T cells in graft-versus-host disease. New England J Med 365(22). https:\/\/doi.org\/10.1056\/NEJMoa1108188","DOI":"10.1056\/NEJMoa1108188"},{"issue":"22","key":"7706_CR55","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1056\/NEJMoa1105143","volume":"365","author":"D Saadoun","year":"2011","unstructured":"Saadoun D, Rosenzwajg M, Joly F et al (2011) Regulatory t-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N Engl J Med 365(22):2067\u20132077. https:\/\/doi.org\/10.1056\/NEJMoa1105143","journal-title":"N Engl J Med"},{"issue":"9","key":"7706_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2022.104911","volume":"25","author":"X Gao","year":"2022","unstructured":"Gao X, He J, Sun X, Li F (2022) Dynamically modeling the effective range of IL-2 dosage in the treatment of systemic lupus erythematosus. iScience 25(9):104911. https:\/\/doi.org\/10.1016\/j.isci.2022.104911","journal-title":"iScience"},{"issue":"8","key":"7706_CR57","doi-asserted-by":"publisher","first-page":"2820","DOI":"10.1093\/rheumatology\/keac711","volume":"62","author":"TM Chan","year":"2023","unstructured":"Chan TM, Wu CE, Yu HH et al (2023) Fetal-neonatal and maternal outcomes in women with Sj\u00f6gren syndrome: a population-based registry linkage study. Rheumatology (Oxford) 62(8):2820\u20132828. https:\/\/doi.org\/10.1093\/rheumatology\/keac711","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"7706_CR58","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1136\/ard.61.6.554","volume":"61","author":"C Vitali","year":"2002","unstructured":"Vitali C, Bombardieri S, Jonsson R et al (2002) Classification criteria for Sj\u00f6gren\u2019s syndrome: a revised version of the European criteria proposed by the American-European consensus group. Ann Rheum Dis 61(6):554\u2013558. https:\/\/doi.org\/10.1136\/ard.61.6.554","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"7706_CR59","doi-asserted-by":"publisher","first-page":"5345","DOI":"10.4049\/jimmunol.165.9.5345","volume":"165","author":"ME Miranda-Car\u00fas","year":"2000","unstructured":"Miranda-Car\u00fas ME, Askanase AD, Clancy RM et al (2000) Anti-SSA\/Ro and anti-SSB\/La autoantibodies bind the surface of apoptotic fetal cardiocytes and promote secretion of TNF-alpha by macrophages. J Immunol 165(9):5345\u20135351. https:\/\/doi.org\/10.4049\/jimmunol.165.9.5345","journal-title":"J Immunol"},{"key":"7706_CR60","doi-asserted-by":"publisher","unstructured":"National Clinical Research Center for Skin and Immune Diseases, National Clinical Research Center for Obstetrics and Gynecology, Chinese Committee on Reproduction and Pregnancy in Rheumatic and Immune Diseases, et al (2022) Chinese guidelines for the management of reproduction and pregnancy in systemic lupus erythematosus patients. Chinese J Internal Med 61(11): 22. https:\/\/doi.org\/10.3760\/cma.j.cn112138-20220821-00612","DOI":"10.3760\/cma.j.cn112138-20220821-00612"},{"issue":"3","key":"7706_CR61","doi-asserted-by":"publisher","first-page":"B41","DOI":"10.1016\/j.ajog.2022.09.001","volume":"228","author":"R Silver","year":"2023","unstructured":"Society for Maternal-Fetal Medicine (SMFM), Silver R, Craigo S et al (2023) Society for maternal-fetal medicine consult series #64: systemic lupus erythematosus in pregnancy. Am J Obstet Gynecol 228(3):B41\u2013B60. https:\/\/doi.org\/10.1016\/j.ajog.2022.09.001","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"7706_CR62","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s12026-016-8888-5","volume":"65","author":"N Mart\u00ednez-S\u00e1nchez","year":"2017","unstructured":"Mart\u00ednez-S\u00e1nchez N, P\u00e9rez-Pinto S, Robles-Marhuenda \u00c1 et al (2017) Obstetric and perinatal outcome in anti-Ro\/SSA-positive pregnant women: a prospective cohort study. Immunol Res 65(2):487\u2013494. https:\/\/doi.org\/10.1007\/s12026-016-8888-5","journal-title":"Immunol Res"},{"issue":"10","key":"7706_CR63","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1136\/ard.2009.119263","volume":"69","author":"PM Izmirly","year":"2010","unstructured":"Izmirly PM, Kim MY, Llanos C et al (2010) Evaluation of the risk of anti-SSA\/Ro-SSB\/La antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine. Ann Rheum Dis 69(10):1827\u20131830. https:\/\/doi.org\/10.1136\/ard.2009.119263","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"7706_CR64","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1161\/CIRCULATIONAHA.111.089268","volume":"126","author":"PM Izmirly","year":"2012","unstructured":"Izmirly PM, Costedoat-Chalumeau N, Pisoni CN et al (2012) Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA\/Ro-antibody-associated cardiac manifestations of neonatal lupus. Circulation 126(1):76\u201382. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.111.089268","journal-title":"Circulation"}],"updated-by":[{"DOI":"10.1007\/s10067-025-07884-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T00:00:00Z","timestamp":1766707200000}}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07706-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-025-07706-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07706-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T09:41:38Z","timestamp":1769679698000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-025-07706-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,28]]},"references-count":64,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["7706"],"URL":"https:\/\/doi.org\/10.1007\/s10067-025-07706-3","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,28]]},"assertion":[{"value":"24 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2025","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: In the original version of this article, the given and family names were incorrectly structured. The names were displayed incorrectly in all versions at the time of publication. The correct author name should be: Yingqian Mo, Wenjing Yang, Yingxin Li, Lie Dai.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2025","order":9,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":10,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s10067-025-07884-0","URL":"https:\/\/doi.org\/10.1007\/s10067-025-07884-0","order":12,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The manuscript does not contain clinical studies or patient data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}},{"value":"The authors report there are no competing interests to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}